NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Institute of Medicine (US) Committee to Study Medication Development and Research at the National Institute on Drug Abuse; Fulco CE, Liverman CT, Earley LE, editors. Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington (DC): National Academies Press (US); 1995.
Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector.
Show details- AAPAA
American Academy of Psychiatrists in Alcoholism and Addiction
- ABMS
American Board of Medical Specialties
- ABPN
American Board of Psychiatry and Neurology
- ACTH
adrenocorticotrophic hormone
- ADAMHA
Alcohol, Drug Abuse, and Mental Health Administration
- ADD
Antiepileptic Drug Development Program
- ADEPT
Alcohol and Drug Education for Physician Training
- AFDC
Aid to Families with Dependent Children
- AIDS
acquired immune deficiency syndrome
- ALS
amyotrophic lateral sclerosis (Lou Gehrig's disease)
- AMBHA
American Managed Behavioral Healthcare Association
- AMERSA
Association for Medical Education and Research in Substance Abuse
- AMP
adenosine 3'5'-monophosphate
- ASAM
American Society of Addiction Medicine
- ATC
addiction training center
- AZT
zidovudine
- BDC
BioDevelopment Corporation
- BJS
Bureau of Justice Statistics
- BLS
Bureau of Labor Statistics
- BSMD
Biobehavioral Sciences and Mental Disorders
- CALDATA
California Drug and Alcohol Treatment Assessment
- CASA
Center on Addiction and Substance Abuse
- CBO
Congressional Budget Office
- CDC
Centers for Disease Control and Prevention
- CDDA
Commission on Medicines for Treatment of Drug Dependence and Abuse
- CDER
Center for Drug Evaluation and Research
- CDP
chemical dependency programs
- CME
continuing medical education
- CMHS
Center for Mental Health Services
- CNS
central nervous system
- CPDD
College on Problems of Drug Dependence
- CRADAs
cooperative research and development agreements
- CRS
Congressional Research Service
- CSA
Controlled Substances Act
- CSAP
Center for Substance Abuse Prevention
- CSAT
Center for Substance Abuse Treatment
- CTDP
Cocaine Treatment Discovery Program
- DAWN
Drug Abuse Warning Network
- DD
drug-discrimination test
- DEA
Drug Enforcement Agency
- DHHS
U.S. Department of Health and Human Services
- DPC-PTR
Drug Price Competition and Patent Term Restoration Act
- DSRS
Drug Services Research Survey
- DVA
Department of Veterans Affairs
- FDA
Food and Drug Administration
- FDCA
Federal Food, Drug, and Cosmetic Act
- FTEs
full-time equivalent personnel
- FY
fiscal year
- GAO
General Accounting Office
- HIV
human immunodeficiency virus
- HMO
health maintenance organization
- HRSA
Health Resources and Services Administration
- IDU
injecting drug-user
- IND
investigational new drug
- IOM
Institute of Medicine
- IRB
institutional review board
- K20
Scientist Development Award for Clinicians
- K21
Scientist Development Award
- LAAM
levo-alpha-acetylmethadol (trade name ORLAAM)
- LMA
locomotor-activity test
- LRP
Loan Repayment Program
- MARC
Minority Access to Research Careers
- MDD
Medications Development Division
- MDMA
Methylenedioxymethamphetamine ("ecstacy")
- MSH
melanocyte-stimulating hormone
- NAS
National Academy of Sciences
- NASADAD
National Association of State Alcohol and Drug Abuse Directors, Inc.
- NATA
Narcotic Addict Treatment Act
- NCDDG-AIDS
National Cooperative Drug Discovery Groups on Acquired Immune Deficiency Syndrome
- NCI
National Cancer Institute
- NCJA
National Criminal Justice Association
- NDA
new drug application
- NDATUS
National Drug and Alcoholism Treatment Survey
- NIAAA
National Institute on Alcohol Abuse and Alcoholism Administration
- NIAID
National Institute of Allergy and Infectious Diseases
- NIDA
National Institute on Drug Abuse
- NIH
National Institutes of Health
- NRC
National Research Council
- NRSA
National Research Service Awards
- ODF
out-patient drug-free
- ONDCP
Office of National Drug Control Policy
- OPRR
Office of Protection from Research Risks
- ORLAAM™
levo-alpha-acetylmethadol (LAAM)
- OTA
Office of Technology Assessment
- PBMs
pharmaceutical benefit managers
- PCP
phencyclidine
- PhRMA
Pharmaceutical Research and Manufacturers of America
- PHS
Public Health Service
- PMA
Pharmaceutical Manufacturers Association
- POMC
pro-opiomelanocortin
- R&D
research and development
- R01
investigator-initiated grants
- R18
research-demonstration grants
- SA
self-administration test
- SADAP
State Alcohol and Drug Abuse Profile
- SAMHSA
Substance Abuse and Mental Health Services Administration
- SSI
Supplemental Security Income
- TB
tuberculosis
- Tcs
therapeutic communities
- TOPS
Treatment Outcome Prospective Study
- TRUs
treatment research units
- VA
Department of Veterans Affairs
- WHO
World Health Organization
- Acronyms - Development of Medications for the Treatment of Opiate and Cocaine Ad...Acronyms - Development of Medications for the Treatment of Opiate and Cocaine Addictions
Your browsing activity is empty.
Activity recording is turned off.
See more...